)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals (ZNTL) investor relations material
Zentalis Pharmaceuticals Leerink Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leerink Global Healthcare Conference 2026 summary9 Mar, 2026
Program highlights and clinical development
Focused on developing azenosertib, a Wee1 inhibitor, for platinum-resistant ovarian cancer with high cyclin E1 expression, with DENALI Part 2 trial ongoing for accelerated approval.
Enrollment for DENALI Part 2's dose comparison (300 mg vs 400 mg) completed, with a phase 3 confirmatory trial (ASPENOVA) set to begin in the same population.
DENALI trial readout expected by year-end 2026, with ASPENOVA designed as a randomized controlled trial to support full approval.
Historical studies showed consistent response rates above 30% and manageable tolerability, especially at 400 mg.
Dose selection in DENALI is based on efficacy and safety, with the selected dose moving forward for primary outcome analysis.
Clinical landscape and regulatory considerations
Standard of care for platinum-resistant ovarian cancer yields low response rates (4%-13%) and minimal PFS benefit, highlighting high unmet need, especially for cyclin E1 high patients.
Mirvetuximab has shown ~30% response rates and 5-6 months duration, setting a benchmark for new therapies.
Regulatory bar for approval is considered around 30% ORR and 5-6 months duration, with examples like mirvetuximab and CDK4/6 inhibitors cited.
ASPENOVA uses an adaptive design to allow early initiation before DENALI readout, aiming for rapid progression to full approval.
ASPENOVA targets 420-450 patients, with site expansion planned beyond DENALI.
Expansion strategies and future directions
MIRROR trial will explore azenosertib in combination with bevacizumab in second-line maintenance for patients progressing on PARP inhibitors, aiming for early proof of concept.
MIRROR will enroll a mix of HRD positive and negative patients, reflecting real-world practice.
CCNE1 and HRD status are not mutually exclusive; retrospective analysis will assess biomarker impact.
Earlier line strategies are being considered, with pragmatic trial designs to efficiently generate data for broader indications.
Ongoing engagement with regulatory agencies to align trial design and enrollment with evolving approval requirements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Zentalis Pharmaceuticals
- Azenosertib shows >30% ORR and ~6 months mDOR in Cyclin E1+ PROC, advancing to Phase 3.ZNTL
Corporate presentation13 Mar 2026 - Azenosertib shows promise for PROC patients, with pivotal trials progressing toward 2026 readouts.ZNTLTD Cowen 46th Annual Health Care Conference3 Mar 2026
- Azenosertib advances as an oral, non-chemo therapy for PROC with pivotal trials and FDA alignment.ZNTLOppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026
- Azenosertib targets platinum-resistant ovarian cancer with high cyclin E1, advancing via adaptive trials.ZNTLGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- FDA paused new enrollment in azenosertib monotherapy trials after sepsis deaths; key data due in 2H 2024.ZNTLStudy Update3 Feb 2026
- Azenosertib shows >30% ORR and ~5.5 months mDOR in Cyclin E1+ PROC, advancing toward approval.ZNTLStudy Update9 Jan 2026
- Azenasertib targets a large, high-need ovarian cancer population with top-line data due in 2026.ZNTLWells Fargo 20th Annual Healthcare Conference 202531 Dec 2025
- Azenosertib shows >30% response in Cyclin E1+ PROC, with seamless trials and strong financial runway.ZNTLTD Cowen 45th Annual Healthcare Conference26 Dec 2025
- Azenosertib shows >30% ORR and strong safety in Cyclin E1+ PROC, with pivotal trials ongoing.ZNTLLeerink Global Healthcare Conference 202526 Dec 2025
Next Zentalis Pharmaceuticals earnings date
Q4 202520 Mar, 2026
Zentalis Pharmaceuticals
Next Zentalis Pharmaceuticals earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Zentalis Pharmaceuticals Inc., operating under the ticker ZNTL on the NASDAQ, is a clinical-stage biopharmaceutical company with a dedicated focus on the discovery and development of small molecule therapeutics aimed at various cancer types. Its pipeline includes a variety of compounds in different stages of clinical trials, targeting key biological pathways in cancer. Zentalis Pharmaceuticals is headquartered in NYC and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage